Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sh-Polypeptide-9, also known as CG-VEGF or Vascular Endothelial Growth Factor Substitute Peptide, is a synthetic recombinant biomimetic peptide designed to replicate the biological activity of endogenous vascular endothelial growth factor (VEGF). Developed primarily by Caregen, this peptide acts as an agonist for VEGF receptors, particularly VEGFR-2, thereby stimulating angiogenesis, promoting microcirculation, and enhancing the delivery of nutrients to tissues such as hair follicles and skin cells. It is widely utilized in aesthetic medicine and dermatology, specifically in injectable hair fillers (e.g., Dr. CYJ Hair Filler) and topical treatments for androgenetic alopecia and skin rejuvenation. By activating the VEGF signaling pathway, it encourages the proliferation of endothelial cells and dermal papilla cells, supporting the growth phase of the hair cycle and improving tissue repair and vascularization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sh-Polypeptide-9.